Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation

被引:24
|
作者
Bruserud, O [1 ]
Ulvestad, E
机构
[1] Univ Bergen, Haukeland Univ Hosp, Gade Inst, Med Dept,Div Hematol, N-5021 Bergen, Norway
[2] Univ Bergen, Haukeland Univ Hosp, Gade Inst, Dept Microbiol & Immunol, N-5021 Bergen, Norway
关键词
acute myelogenous leukemia; T lymphocytes; costimulation; cytokine;
D O I
10.1006/cimm.2000.1725
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The ability of acute myelogenous leukemia (AML) blasts to mediate costimulatory signals during T lymphocyte activation was investigated in an experimental model where monoclonal T cell populations were stimulated with standardized activation signals (anti-CD3, anti-CD2, and anti-CD28 monoclonal antibodies and phytohemagglutinin). Proliferative T cell responses were detected for all AML patients (n = 16) when irradiated leukemia blasts were used as accessory cells during activation, T cell cytokine release was also observed for all patients when nonirradiated AML accessory cells were used, and for most patients a broad cytokine response (interleukin (IL) 2, IL4, IL10, IL13, and interferon-gamma) was detected. However, both T cell proliferation and cytokine release showed a wide variation among AML patients, and T cell responsiveness was in addition dependent both on the nature of the activation signal and on differences between individual T cell clones. The accessory cell function of AML blasts showed no correlation with the release of any single immunomodulatory soluble mediator (IL1 beta, IL6, TNF-alpha, soluble IL2 receptors) or the expression of any particular adhesion/costimulatory membrane molecule (CD54, CD58, CD80, and CD86) by the blasts. However, blocking studies with anti-CD58 and anti-CD80/86 monoclonal antibodies demonstrated that both pathways can be involved when AML blasts are used as accessory cells, but the relative importance and the Anal effects of signaling through these pathways differ between AML populations. Although there is a wide interpatient variation, we conclude that for a majority of patients the native AML blasts can mediate adequate costimulatory signals needed for accessory cell-dependent T cell activation. (C) 2000 Academic Press.
引用
收藏
页码:36 / 50
页数:15
相关论文
共 50 条
  • [31] Accumulation of arabinosyluracil 5′-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia
    Gandhi, V
    Xu, YZ
    Estey, E
    CLINICAL CANCER RESEARCH, 1998, 4 (07) : 1719 - 1726
  • [32] Effects of azoles on human acute myelogenous leukemia blasts and T lymphocytes derived from acute leukemia patients with chemotherapy-induced cytopenia
    Bruserud, O
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (12) : 2183 - 2195
  • [33] Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells
    Köhler, T
    Plettig, R
    Wetzstein, W
    Schmitz, M
    Ritter, M
    Mohr, B
    Schaekel, U
    Ehninger, G
    Bornhäuser, M
    STEM CELLS, 2000, 18 (02) : 139 - 147
  • [34] Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts
    Hatfield, Kimberley
    Ryningen, Anita
    Corbascio, Matthias
    Bruserud, Oystein
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (10) : 2313 - 2321
  • [35] Acute myelogenous leukemia cells change into fibroblast cells morphologically and functionally during in vitro long-term culture
    Tashiro, H.
    Noguchi, M.
    Shirasaki, R.
    Shirafuji, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 120 - 120
  • [36] Effect of vesnarinone, a quinolinone derivative, on the growth of leukemic blasts in acute myelogenous leukemia
    Nara, N
    Kurokawa, H
    Tohda, S
    Tomiyama, J
    Nagata, K
    Tanikawa, S
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (03) : 199 - 204
  • [37] Myeloblasts convert into fibroblastoid stromal cells to create a microenvironment for proliferation of leukemia blasts in acute and chronic myelogenous leukemia cases.
    Tashiro, Haruko
    Noguchi, Mitsuho
    Shirasaki, Ryosuke
    Gotoh, Moritaka
    Kawasugi, Kazuo
    Shirafuji, Naoki
    BLOOD, 2006, 108 (11) : 140B - 140B
  • [38] In vitro cytotoxicity of the LDE:daunorubicin complex in acute myelogenous leukemia blast cells
    Dorlhiac-Llacer, PE
    Marquezini, MV
    Toffoletto, O
    Carneiro, RCG
    Maranhao, RC
    Chamone, DAF
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2001, 34 (10) : 1257 - 1263
  • [39] Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses
    Choudhury, A
    Liang, JC
    Thomas, EK
    Flores-Romo, L
    Xie, QS
    Agusala, K
    Sutaria, S
    Sinha, I
    Champlin, RE
    Claxton, DF
    BLOOD, 1999, 93 (03) : 780 - 786
  • [40] In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media:: Studies of native AML blasts and AML cell lines
    Bruserud, O
    Gjertsen, BT
    Von Volkman, HL
    JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (06): : 923 - 932